By Leroy Leo, Aditya Samal2 Min ReadFILE PHOTO: The Johnson & Johnson emblem is displayed on a display screen on the ground of the New York Stock Exchange (NYSE) in New York, U.S., May 29, 2019. REUTERS/Brendan McDermid/File Photo(Reuters) – Johnson & Johnson will search for alternatives to merge with or purchase corporations that add worth to its focus areas of eye care, surgical robots, orthopedics and cardiovascular merchandise, the corporate’s Chief Executive Officer Joaquin Duato stated on Monday.The healthcare large is within the technique of spinning off its shopper healthcare enterprise underneath the model Kenvue to concentrate on its pharmaceutical and medical units companies.“We’ll continue to be disciplined in looking for opportunities in which we can create value that serve a significant unmet medical need like heart failure,” Duato stated on the J.P. Morgan Healthcare Conference.J&J final month accomplished its acquisition of coronary heart pump maker Abiomed for $16.6 billion, which can function as an impartial division in its medical units enterprise.Duato stated lots of its future offers would doubtless be small “tuck-in” acquisitions.The firm’s CEO expects J&J to proceed rising in the direction of its purpose of $60 billion in pharmaceutical gross sales by 2025, and is assured of exceeding present Street expectations by the focused 12 months.Reporting by Leroy Leo and Aditya Samal; Editing by Krishna Chandra EluriOur Standards: The Thomson Reuters Trust Principles.